House Bill 2103 directs the Oregon State Board of Pharmacy to adopt rules classifying xylazine as a Schedule IV controlled substance. Xylazine is a veterinary sedative and tranquilizer that has also been identified in illicit drug supply, so the bill would place it under Oregon’s controlled-substance framework rather than leaving its classification unchanged.
The measure is narrow and administrative in form: it does not itself amend the controlled-substance schedules in statute, but instead instructs the Board of Pharmacy to make the classification by rule. If adopted, the bill would bring xylazine within Schedule IV controls under Oregon law, affecting pharmacists, prescribers, veterinarians, distributors, and law enforcement by subjecting the substance to tighter regulation, handling, and enforcement standards.
Impact
HB 2103 would add xylazine to Oregon’s controlled-substance regime by requiring the State Board of Pharmacy to classify it as a Schedule IV drug through rulemaking. This would affect ORS 475.005 to 475.285 by inserting a new directive into the controlled-substances chapter and would likely change how xylazine is manufactured, dispensed, possessed, and monitored in Oregon. The practical impact would fall on pharmacies, veterinary practices, healthcare providers, and regulatory and enforcement agencies.
Sentiment
There is no recorded committee testimony or vote history in the provided materials, so the bill’s sentiment cannot be measured from debate or roll calls. Based on the text alone, the measure appears straightforward and technical, with an apparent public-safety or regulatory purpose rather than a controversial policy overhaul.
Contention
No specific points of contention are documented in the available transcript or voting materials. Potential areas of concern, if raised later, would likely involve whether xylazine should be scheduled at all, whether Schedule IV is the appropriate level, and how the rulemaking directive might affect veterinary use, medical access, and enforcement against illicit drug diversion.